Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 501

1.

Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population.

Vestbo J, Vogelmeier CF, Small M, Siddall J, Fogel R, Kostikas K.

Int J Chron Obstruct Pulmon Dis. 2019 Apr 16;14:853-861. doi: 10.2147/COPD.S189585. eCollection 2019.

2.

Outcomes reported on the management of COPD exacerbations: a systematic survey of randomised controlled trials.

Mathioudakis AG, Moberg M, Janner J, Alonso-Coello P, Vestbo J.

ERJ Open Res. 2019 May 10;5(2). pii: 00072-2019. doi: 10.1183/23120541.00072-2019. eCollection 2019 Apr.

3.

Plasma microfibrillar-associated protein 4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patients.

Johansson SL, Wulf-Johansson H, Schlosser A, Titlestad IL, Miller B, Tal-Singer R, Holmskov U, Vestbo J, Sørensen GL.

ERJ Open Res. 2019 Apr 15;5(2). pii: 00021-2019. doi: 10.1183/23120541.00021-2019. eCollection 2019 Apr.

4.

Type IV collagen turnover is predictive of mortality in COPD: a comparison to fibrinogen in a prospective analysis of the ECLIPSE cohort.

Rønnow SR, Sand JMB, Langholm LL, Manon-Jensen T, Karsdal MA, Tal-Singer R, Miller BE, Vestbo J, Leeming DJ.

Respir Res. 2019 Apr 1;20(1):63. doi: 10.1186/s12931-019-1026-x.

5.

Regional Differences in Rate of FEV1 decline in COPD: Lessons from SUMMIT.

Celli BR, Anderson JA, Brook RD, Calverley PMA, Cowans NJ, Crim C, Martinez F, Newby DE, Yates J, Vestbo J.

Eur Respir J. 2019 Mar 28. pii: 1900278. doi: 10.1183/13993003.00278-2019. [Epub ahead of print] No abstract available.

PMID:
30923182
6.

Chronic Airway Diseases Early Stratification (CADSET): a new ERS Clinical Research Collaboration.

Agusti A, Faner R, Donaldson G, Heuvelin E, Breyer-Kohansal R, Melén E, Maitland-van der Zee AH, Vestbo J, Allinson JP, Vanfleteren LEGW, van den Berge M, Adcock IM, Lahousse L, Brusselle G, Wedzicha JA; on behalf of the CADSET Clinical Research Collaboration; Current members of the CADSET Clinical Research Collaboration.

Eur Respir J. 2019 Mar 18;53(3). pii: 1900217. doi: 10.1183/13993003.00217-2019. Print 2019 Mar. No abstract available.

PMID:
30886026
7.

Specific elastin degradation products are associated with poor outcome in the ECLIPSE COPD cohort.

Rønnow SR, Langholm LL, Sand JMB, Thorlacius-Ussing J, Leeming DJ, Manon-Jensen T, Tal-Singer R, Miller BE, Karsdal MA, Vestbo J.

Sci Rep. 2019 Mar 11;9(1):4064. doi: 10.1038/s41598-019-40785-2.

8.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.

Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, López Varela MV, Martinez F, Montes de Oca M, Papi A, Pavord ID, Roche N, Sin DD, Stockley R, Vestbo J, Wedzicha JA, Vogelmeier C.

Eur Respir J. 2019 May 18;53(5). pii: 1900164. doi: 10.1183/13993003.00164-2019. Print 2019 May. Review.

PMID:
30846476
9.

Association of Cardiovascular Disease With Respiratory Disease.

Carter P, Lagan J, Fortune C, Bhatt DL, Vestbo J, Niven R, Chaudhuri N, Schelbert EB, Potluri R, Miller CA.

J Am Coll Cardiol. 2019 May 7;73(17):2166-2177. doi: 10.1016/j.jacc.2018.11.063. Epub 2019 Mar 4.

PMID:
30846341
10.

Was the implementation strategy of the ProACT trial adequately proactive?

Mathioudakis AG, Vestbo J.

Breathe (Sheff). 2019 Mar;15(1):77-80. doi: 10.1183/20734735.0338-2018.

11.

Impact of pre-enrolment medication use on clinical outcomes in SUMMIT.

Vestbo J, Dransfield M, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Martinez F, Newby DE, Yates J, Lange P.

ERJ Open Res. 2019 Feb 25;5(1). pii: 00203-2018. doi: 10.1183/23120541.00203-2018. eCollection 2019 Feb.

12.

Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations.

Sakornsakolpat P, Prokopenko D, Lamontagne M, Reeve NF, Guyatt AL, Jackson VE, Shrine N, Qiao D, Bartz TM, Kim DK, Lee MK, Latourelle JC, Li X, Morrow JD, Obeidat M, Wyss AB, Bakke P, Barr RG, Beaty TH, Belinsky SA, Brusselle GG, Crapo JD, de Jong K, DeMeo DL, Fingerlin TE, Gharib SA, Gulsvik A, Hall IP, Hokanson JE, Kim WJ, Lomas DA, London SJ, Meyers DA, O'Connor GT, Rennard SI, Schwartz DA, Sliwinski P, Sparrow D, Strachan DP, Tal-Singer R, Tesfaigzi Y, Vestbo J, Vonk JM, Yim JJ, Zhou X, Bossé Y, Manichaikul A, Lahousse L, Silverman EK, Boezen HM, Wain LV, Tobin MD, Hobbs BD, Cho MH; SpiroMeta Consortium; International COPD Genetics Consortium.

Nat Genet. 2019 Mar;51(3):494-505. doi: 10.1038/s41588-018-0342-2. Epub 2019 Feb 25.

PMID:
30804561
13.

Prospective observational study in patients with obstructive lung disease: NOVELTY design.

Reddel HK, Gerhardsson de Verdier M, Agustí A, Anderson G, Beasley R, Bel EH, Janson C, Make B, Martin RJ, Pavord I, Price D, Keen C, Gardev A, Rennard S, Sveréus A, Bansal AT, Brannman L, Karlsson N, Nuevo J, Nyberg F, Young SS, Vestbo J.

ERJ Open Res. 2019 Feb 1;5(1). pii: 00036-2018. doi: 10.1183/23120541.00036-2018. eCollection 2019 Feb.

14.

Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups.

Bakerly ND, Woodcock A, Collier S, Leather DA, New JP, Crawford J, Harvey C, Vestbo J, Boucot I.

Respir Med. 2019 Feb;147:58-65. doi: 10.1016/j.rmed.2018.12.016. Epub 2019 Jan 10.

15.

Surfactant Protein D Deficiency Aggravates Cigarette Smoke-Induced Lung Inflammation by Upregulation of Ceramide Synthesis.

Pilecki B, Wulf-Johansson H, Støttrup C, Jørgensen PT, Djiadeu P, Nexøe AB, Schlosser A, Hansen SWK, Madsen J, Clark HW, Nielsen CH, Vestbo J, Palaniyar N, Holmskov U, Sorensen GL.

Front Immunol. 2018 Dec 18;9:3013. doi: 10.3389/fimmu.2018.03013. eCollection 2018.

16.

Automated oxygen control with O2matic® during admission with exacerbation of COPD.

Hansen EF, Hove JD, Bech CS, Jensen JS, Kallemose T, Vestbo J.

Int J Chron Obstruct Pulmon Dis. 2018 Dec 14;13:3997-4003. doi: 10.2147/COPD.S183762. eCollection 2018.

17.

The Manchester Respiratory-related Sleep Symptoms scale for patients with COPD: development and validation.

Khan N, Vestbo J, Garrow A, Karur P, Kolsum U, Tyson S, Singh D, Yorke J.

Int J Chron Obstruct Pulmon Dis. 2018 Nov 29;13:3885-3894. doi: 10.2147/COPD.S171140. eCollection 2018.

18.

What is the impact of GOLD 2017 recommendations in primary care? - a descriptive study of patient classifications, treatment burden and costs.

Gayle A, Dickinson S, Morris K, Poole C, Mathioudakis AG, Vestbo J.

Int J Chron Obstruct Pulmon Dis. 2018 Oct 23;13:3485-3492. doi: 10.2147/COPD.S173664. eCollection 2018. Erratum in: Int J Chron Obstruct Pulmon Dis. 2018 Dec 05;13:3899.

19.

Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee.

Criner GJ, Martinez FJ, Aaron S, Agusti A, Anzueto A, Bafadhel M, Barnes PJ, Bourbeau J, Chen R, Ewig J, Fabbri LM, Frith P, Halpin DMG, Han M, Montes de Oca M, Nishimura M, O'Donnell D, Papi A, Pavord I, Roche N, Rodriguez-Roisin R, Salvi S, Singh D, Sin DD, Stockley R, López Varela MV, Vestbo J, Vogelmeier CF, Washko G, Wedzicha JA, Celli BR.

Ann Am Thorac Soc. 2019 Jan;16(1):29-39. doi: 10.1513/AnnalsATS.201808-557PS. No abstract available.

PMID:
30427736
20.

Validation of lung density indices by cardiac CT for quantification of lung emphysema.

Ronit A, Kristensen T, Çolak Y, Kühl JT, Kalhauge A, Lange P, Nordestgaard BG, Vestbo J, Nielsen SD, Kofoed KF.

Int J Chron Obstruct Pulmon Dis. 2018 Oct 11;13:3321-3330. doi: 10.2147/COPD.S172695. eCollection 2018.

21.

Inhaled triple therapy in chronic obstructive pulmonary disease - Authors' reply.

Papi A, Singh D, Petruzzelli S, Guasconi A, Vestbo J.

Lancet. 2018 Sep 29;392(10153):1113-1114. doi: 10.1016/S0140-6736(18)31778-1. No abstract available.

PMID:
30303077
22.

Inhaled corticosteroid containing combinations and mortality in COPD.

Vestbo J, Fabbri L, Papi A, Petruzzelli S, Scuri M, Guasconi A, Vezzoli S, Singh D.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801230. doi: 10.1183/13993003.01230-2018. Print 2018 Dec. No abstract available.

PMID:
30209195
23.

Inhaled corticosteroids in COPD: friend or foe?

Agusti A, Fabbri LM, Singh D, Vestbo J, Celli B, Franssen FME, Rabe KF, Papi A.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801219. doi: 10.1183/13993003.01219-2018. Print 2018 Dec. Review.

PMID:
30190269
24.

Childhood Asthma, Lung Function Trajectories, and Chronic Obstructive Pulmonary Disease: An Additional Step Forward.

Vestbo J.

Ann Am Thorac Soc. 2018 Sep;15(9):1030-1031. doi: 10.1513/AnnalsATS.201807-440ED. No abstract available.

PMID:
30168747
25.

Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease.

Adamson PD, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Dixon IJ, Martinez FJ, Newby DE, Vestbo J, Yates JC, Mills NL.

J Am Coll Cardiol. 2018 Sep 4;72(10):1126-1137. doi: 10.1016/j.jacc.2018.06.051. Erratum in: J Am Coll Cardiol. 2018 Oct 30;72(18):2282.

26.

Diagnostic performance of clinical characteristics to detect airflow limitation in people living with HIV and in uninfected controls.

Ronit A, Benfield T, Mocroft A, Gerstoft J, Nordestgaard BG, Vestbo J, Nielsen SD; Copenhagen Co-morbidity in HIV Infection (COCOMO) Study Group.

HIV Med. 2018 Nov;19(10):751-755. doi: 10.1111/hiv.12669. Epub 2018 Aug 30.

PMID:
30160344
27.

Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial.

Byrd JB, Newby DE, Anderson JA, Calverley PMA, Celli BR, Cowans NJ, Crim C, Martinez FJ, Vestbo J, Yates J, Brook RD; SUMMIT Investigators.

Eur Heart J. 2018 Sep 1;39(33):3128-3134. doi: 10.1093/eurheartj/ehy451.

PMID:
30101300
28.

Whole exome sequencing analysis in severe chronic obstructive pulmonary disease.

Qiao D, Ameli A, Prokopenko D, Chen H, Kho AT, Parker MM, Morrow J, Hobbs BD, Liu Y, Beaty TH, Crapo JD, Barnes KC, Nickerson DA, Bamshad M, Hersh CP, Lomas DA, Agusti A, Make BJ, Calverley PMA, Donner CF, Wouters EF, Vestbo J, Paré PD, Levy RD, Rennard SI, Tal-Singer R, Spitz MR, Sharma A, Ruczinski I, Lange C, Silverman EK, Cho MH.

Hum Mol Genet. 2018 Nov 1;27(21):3801-3812. doi: 10.1093/hmg/ddy269.

PMID:
30060175
29.

Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study.

Svedsater H, Jones R, Bosanquet N, Jacques L, Lay-Flurrie J, Leather DA, Vestbo J, Collier S, Woodcock A.

Respir Med. 2018 Aug;141:198-206. doi: 10.1016/j.rmed.2018.06.003. Epub 2018 Jun 6.

30.

Computed tomography quantification of emphysema in people living with HIV and uninfected controls.

Ronit A, Kristensen T, Hoseth VS, Abou-Kassem D, Kühl JT, Benfield T, Gerstoft J, Afzal S, Nordestgaard BG, Lundgren JD, Vestbo J, Kofoed KF, Nielsen SD; Copenhagen Comorbidity in HIV Infection (COCOMO) study group.

Eur Respir J. 2018 Jul 19;52(1). pii: 1800296. doi: 10.1183/13993003.00296-2018. Print 2018 Jul.

PMID:
29880654
31.

Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease.

Yun JH, Lamb A, Chase R, Singh D, Parker MM, Saferali A, Vestbo J, Tal-Singer R, Castaldi PJ, Silverman EK, Hersh CP; COPDGene and ECLIPSE Investigators.

J Allergy Clin Immunol. 2018 Jun;141(6):2037-2047.e10. doi: 10.1016/j.jaci.2018.04.010. Epub 2018 Apr 28.

PMID:
29709670
32.

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.

Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 10;13:1125-1134. doi: 10.2147/COPD.S160011. eCollection 2018.

33.

Left ventricular volume and wall stress are linked to lung function impairment in COPD.

Alter P, Jörres RA, Watz H, Welte T, Gläser S, Schulz H, Bals R, Karch A, Wouters EFM, Vestbo J, Young D, Vogelmeier CF.

Int J Cardiol. 2018 Jun 15;261:172-178. doi: 10.1016/j.ijcard.2018.02.074.

PMID:
29657040
34.

Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD.

Vedel-Krogh S, Nordestgaard BG, Lange P, Vestbo J, Nielsen SF.

Eur Respir J. 2018 May 24;51(5). pii: 1800120. doi: 10.1183/13993003.00120-2018. Print 2018 May.

PMID:
29650563
35.

The emerging Chinese COPD epidemic.

Vestbo J, Mathioudakis AG.

Lancet. 2018 Apr 28;391(10131):1642-1643. doi: 10.1016/S0140-6736(18)30859-6. Epub 2018 Apr 9. No abstract available.

PMID:
29650249
36.

Effectiveness versus efficacy trials in COPD: how study design influences outcomes and applicability.

Woodcock A, Boucot I, Leather DA, Crawford J, Collier S, Bakerly ND, Hilton E, Vestbo J.

Eur Respir J. 2018 Feb 21;51(2). pii: 1701531. doi: 10.1183/13993003.01531-2017. Print 2018 Feb.

PMID:
29467200
37.

Young and middle-aged adults with airflow limitation according to lower limit of normal but not fixed ratio have high morbidity and poor survival: a population-based prospective cohort study.

Çolak Y, Afzal S, Nordestgaard BG, Vestbo J, Lange P.

Eur Respir J. 2018 Mar 29;51(3). pii: 1702681. doi: 10.1183/13993003.02681-2017. Print 2018 Mar.

PMID:
29449425
38.

Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial.

Kunisaki KM, Dransfield MT, Anderson JA, Brook RD, Calverley PMA, Celli BR, Crim C, Hartley BF, Martinez FJ, Newby DE, Pragman AA, Vestbo J, Yates JC, Niewoehner DE; SUMMIT Investigators.

Am J Respir Crit Care Med. 2018 Jul 1;198(1):51-57. doi: 10.1164/rccm.201711-2239OC.

PMID:
29442524
39.

Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype.

Celli BR, Locantore N, Tal-Singer R, Riley J, Miller B, Vestbo J, Yates JC, Silverman EK, Owen CA, Divo M, Pinto-Plata V, Wouters EFM, Faner R, Agusti A; ECLIPSE Study Investigators.

Eur Respir J. 2018 Feb 7;51(2). pii: 1702146. doi: 10.1183/13993003.02146-2017. Print 2018 Feb.

PMID:
29437944
40.

Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.

Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D.

Lancet. 2018 Mar 17;391(10125):1076-1084. doi: 10.1016/S0140-6736(18)30206-X. Epub 2018 Feb 9. Erratum in: Lancet. 2018 Feb 26;:.

PMID:
29429593
41.

The revised GOLD 2017 COPD categorization in relation to comorbidities.

Kahnert K, Alter P, Young D, Lucke T, Heinrich J, Huber RM, Behr J, Wacker M, Biertz F, Watz H, Bals R, Welte T, Wirtz H, Herth F, Vestbo J, Wouters EF, Vogelmeier CF, Jörres RA.

Respir Med. 2018 Jan;134:79-85. doi: 10.1016/j.rmed.2017.12.003. Epub 2017 Dec 5.

42.

Long-Acting β-Agonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial.

Celli B, Anderson JA, Brook R, Calverley P, Crim C, Holmes AP, Martinez FJ, Newby DE, Yates J, Vestbo J; SUMMIT Investigators.

Am J Respir Crit Care Med. 2018 Jun 15;197(12):1641-1644. doi: 10.1164/rccm.201710-2052LE. No abstract available.

PMID:
29412688
43.

At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease.

Martinez FJ, Han MK, Allinson JP, Barr RG, Boucher RC, Calverley PMA, Celli BR, Christenson SA, Crystal RG, Fagerås M, Freeman CM, Groenke L, Hoffman EA, Kesimer M, Kostikas K, Paine R 3rd, Rafii S, Rennard SI, Segal LN, Shaykhiev R, Stevenson C, Tal-Singer R, Vestbo J, Woodruff PG, Curtis JL, Wedzicha JA.

Am J Respir Crit Care Med. 2018 Jun 15;197(12):1540-1551. doi: 10.1164/rccm.201710-2028PP. No abstract available. Erratum in: Am J Respir Crit Care Med. 2018 Dec 1;198(11):1463.

44.

β-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT.

Dransfield MT, McAllister DA, Anderson JA, Brook RD, Calverley PMA, Celli BR, Crim C, Gallot N, Martinez FJ, Scanlon PD, Yates J, Vestbo J, Newby DE; SUMMIT Investigators.

Ann Am Thorac Soc. 2018 May;15(5):608-614. doi: 10.1513/AnnalsATS.201708-626OC.

PMID:
29406772
45.

Cigarette smoking and response to inhaled corticosteroids in COPD.

Bhatt SP, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Martinez FJ, Newby DE, Vestbo J, Yates JC, Dransfield MT.

Eur Respir J. 2018 Jan 18;51(1). pii: 1701393. doi: 10.1183/13993003.01393-2017. Print 2018 Jan. No abstract available.

PMID:
29348179
46.

Airflow limitation in people living with HIV and matched uninfected controls.

Ronit A, Lundgren J, Afzal S, Benfield T, Roen A, Mocroft A, Gerstoft J, Nordestgaard BG, Vestbo J, Nielsen SD; Copenhagen Co-morbidity in HIV infection (COCOMO) study group.

Thorax. 2018 May;73(5):431-438. doi: 10.1136/thoraxjnl-2017-211079. Epub 2018 Jan 13.

PMID:
29331988
47.

Pulmonary rehabilitation for patients with COPD during and after an exacerbation-related hospitalisation: back to the future?

Wilson KC, Krishnan JA, Sliwinski P, Criner GJ, Miravitlles M, Hurst JR, Calverley PMA, Albert RK, Rigau D, Tonia T, Vestbo J, Papi A, Rabe KF, Anzueto A, Wedzicha JA.

Eur Respir J. 2018 Jan 11;51(1). pii: 1702577. doi: 10.1183/13993003.02577-2017. Print 2018 Jan. No abstract available.

PMID:
29326324
48.

Biomarkers of collagen turnover are related to annual change in FEV1 in patients with chronic obstructive pulmonary disease within the ECLIPSE study.

Leeming DJ, Byrjalsen I, Sand JMB, Bihlet AR, Lange P; Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators, Thal-Singer R, Miller BE, Karsdal MA, Vestbo J.

BMC Pulm Med. 2017 Dec 4;17(1):164. doi: 10.1186/s12890-017-0505-4.

49.

Management of Dyspnea and Anxiety in Chronic Obstructive Pulmonary Disease: A Critical Review.

Yohannes AM, Junkes-Cunha M, Smith J, Vestbo J.

J Am Med Dir Assoc. 2017 Dec 1;18(12):1096.e1-1096.e17. doi: 10.1016/j.jamda.2017.09.007. Epub 2017 Nov 3. Review.

PMID:
29108885
50.

Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.

Singh D, Corradi M, Spinola M, Papi A, Usmani OS, Scuri M, Petruzzelli S, Vestbo J.

Int J Chron Obstruct Pulmon Dis. 2017 Oct 6;12:2917-2928. doi: 10.2147/COPD.S146822. eCollection 2017. Review.

Supplemental Content

Loading ...
Support Center